Developer docs
API playgroundTry for free, no card

Search company profiles

Microsize

Full company profile

uuid000ik69

Namestring
Microsize
Legal namestring
Microsize LLC
Websiteurl
microsize.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Microsize is a US-headquartered pharmaceutical contract development and manufacturing organization (CDMO) specializing in particle size reduction, powder classification, and analytical services for small-molecule active pharmaceutical ingredients (APIs) and excipients. The company addresses bioavailability and dissolution challenges for poorly soluble compounds through jet milling and micronization — proprietary equipment designed and built in-house — capable of reducing particles to under 10 microns with ~1 micron variance. Microsize operates three FDA-inspected cGMP facilities totaling over 100,000 sq ft in Quakertown, Pennsylvania, and acquired a fourth GMP facility in Monteggio, Switzerland (Micro-Macinazione) from Lonza in May 2026, creating a dual US-European particle engineering platform.

The company offers end-to-end services spanning feasibility studies (as little as 1-5 grams of API), Phase I-III clinical manufacturing, and commercial production campaigns at multi-metric-ton scale. Differentiated capabilities include Co-Jet Milling (combined size reduction and blending), HPAPI containment qualified to OEB 6 (down to 50 ng/m³), air-swept turbo classification for hydrate stability, and advanced analytical characterization (XRPD, DSC, TGA, DVS, laser diffraction). Microsize has expanded beyond toll micronization into a broader particle engineering ecosystem through partnerships with AustinPx (KinetiSol), The Solubility Company (SPA platform licensing — Microsize is the first US licensee), Persist AI (Micromill platform), and Aspire Biopharma (sublingual alprazolam and aspirin development).

Microsize generates revenue through project-based professional services contracts with pharmaceutical companies ranging from small biotechs to large pharma, as well as other CDMOs and functional excipient manufacturers. Pricing is quote-based, dependent on API type, potency, batch size, and development phase. GTM is high-touch, enterprise field sales with direct technical engagement, supplemented by conference presence (CPhI, ChemOutsourcing), technical whitepapers, and LinkedIn-driven brand building. The company is privately held, launched as an independent entity in July 2022 after separation from Lonza, and inherits the 30-year operational heritage of predecessor Powdersize Inc.

Short descriptiontext

Microsize is a US-headquartered pharmaceutical CDMO specializing in jet milling, micronization, and particle engineering for poorly soluble APIs, operating three FDA-inspected cGMP facilities across 100,000+ sq ft and serving small biotechs through large pharma from feasibility to commercial supply.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersQuakertown, United States
HQ citystring
Quakertown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical micronization, particle size reduction, contract development manufacturing, bioavailability enhancement, HPAPI containment
Industry4 codes
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Plastics Products, Nec3089
Product category
Pharmaceutical CDMO Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Manufacturing Services (CDMO)
TypeProfessional Services
Description

Microsize provides contract development and manufacturing organization services for pharmaceutical micronization and particle size reduction. Revenue is generated through project-based contracts spanning feasibility studies through commercial production campaigns. The company charges for processing services based on project scope, material quantities, and complexity. Services are provided to small biotechs, mid-size pharmaceutical companies, and large pharma organizations.

microsize.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Micromill
Description

First-of-its-kind early-stage formulation platform enabling drug development decisions with milligrams of API, developed in partnership with Persist AI and Micromacinazione.

microsize.com
Core offering1 text field

Microsize is a US-based pharmaceutical contract development and manufacturing organization (CDMO) providing cGMP micronization and particle size reduction services. The company processes APIs and excipients from grams to multi-metric tons, including highly potent compounds, through three FDA-inspected facilities. Core offerings include particle size reduction (micronization/milling), particle classification, analytical characterization, and high-potency containment services for drug developers addressing dissolution and bioavailability challenges.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Feasibility assessments completed in one day with minimal API (as little as 1-5 grams)
+3 more records
Product and service6 records
1Micronization & Particle Size Reduction Services
CategoryPharmaceutical CDMO Services
2Particle Classification Services
CategoryPharmaceutical CDMO Services
3Analytical Characterization Services
CategoryPharmaceutical CDMO Services
4High Potency Containment Services
CategoryPharmaceutical CDMO Services
5Micromill Platform
CategoryPharmaceutical Formulation Technology
6SPA Platform Licensing
CategoryPharmaceutical Analytical Technology
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-03
Description

Strategic collaboration to launch 'Micromill' platform, the world's first integrated system enabling oral formulation decision-making using only milligrams of API. Combines Micmac's SSM20 mini mill with Persist AI's AI-driven experimentation and process analytical technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-04
Description

Partnership to develop first-ever sublingual alprazolam powder formulation for faster anxiety relief. Phase 1 clinical trial planned for mid-2026, targeting a medication with over 15.8 million US prescriptions in 2023.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-24
Description

Joint acquisition of Micro-Macinazione (Micmac) from Lonza to establish integrated European-American network for advanced particle engineering. Schedio contributes process equipment and containment technologies while Microsize provides CDMO expertise. Transaction closed May 2026.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-16
Description

Microsize became the first US licensee for The Solubility Company's SPA platform, a novel solubility measuring technology. Strategic investment to accelerate US expansion of this disruptive technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-01
Description

Expanded CDMO relationship for commercial supply of MAXIGESIC/COMBOGESIC products with investments in capacity expansion.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-02-26
Description

Expanded CDMO relationship with Cerus Corporation for pharmaceutical manufacturing services.

7AustinPx
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-01-31
Description

Partnership on KinetiSol technology for novel particle size technology, enabling development of products using this advanced formulation approach.

microsize.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Halo Pharma is a specialty CDMO focused on oral solid dosage form development and manufacturing. It competes with Microsize for bioavailability-limited drug product work where particle engineering and formulation overlap, particularly for small and mid-size pharma customers.

TypeDirect peer
Description

Hovione is a Portugal-headquartered global CDMO with deep particle engineering and jet milling capabilities for small-molecule APIs. It competes most directly with Microsize across micronization, HPAPI containment, and bioavailability-enhancement services, serving similar biotech-to-big-pharma customers with overlapping technology offerings.

TypeBroad incumbent
Description

Lonza is one of the largest global CDMOs and historically operated the Quakertown and Micro-Macinazione facilities that Microsize acquired. While Lonza offers micronization as part of a far broader CDMO portfolio, its scale and breadth make it a frequent alternative or competitor for bioavailability-limited small-molecule programs.

TypeBroad incumbent
Description

Evotec is a global contract development and manufacturing organization with capabilities spanning drug substance, drug product, and integrated pharmaceutical services. It competes with Microsize for formulation and bioavailability-enhancement projects, particularly with European biotech customers after Microsize's Micro-Macinazione expansion.

TypeBroad incumbent
Description

Catalent is a large global CDMO offering a wide range of drug product services including particle engineering, bioavailability enhancement, and HPAPI handling. It competes with Microsize at the high end of the market by bundling micronization into broader end-to-end development and manufacturing contracts.

TypeEmerging player
Description

Aprecia is a specialty pharma company and CDMO using binder-jetting 3D printing for oral dosage forms. It is an emerging player in the broader particle-engineering and bioavailability space, intersecting with Microsize's territory through novel oral drug delivery approaches for poorly soluble compounds.

TypeDirect peer
Description

Ascendia Pharmaceuticals is a specialty CDMO focused on nano-milling and formulation development for poorly soluble compounds. It directly competes with Microsize in providing bioavailability-enhancement and particle engineering services, often at similar early-stage customer touchpoints.

TypeBroad incumbent
Description

Thermo Fisher's pharma services business, built around Patheon, is a major global CDMO offering drug substance, drug product, and bioavailability-enhancement services. It is a broad incumbent competitor for Microsize's biotech and large pharma customers across micronization-adjacent formulation work.

9Lubrizol Life Sciences (Particle Sciences)
TypeDirect peer
Description

Lubrizol Life Sciences, through its Particle Sciences business, is a CDMO focused on particle engineering, formulation development, and drug product manufacturing. It directly competes with Microsize in micronization and bioavailability-enhancement services for poorly soluble APIs across a similar customer base of small to mid-size pharma.

TypeBroad incumbent
Description

Eurofins operates a CDMO and contract testing portfolio that overlaps with Microsize's analytical characterization and formulation-support offerings. It is a broader incumbent that competes for outsourced pharmaceutical development and quality services across both US and European markets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Microsize

Pharmaceutical CDMO Servicesmicrosize.com

Microsize is a US-headquartered pharmaceutical CDMO specializing in jet milling, micronization, and particle engineering for poorly soluble APIs, operating three FDA-inspected cGMP facilities across 100,000+ sq ft and serving small biotechs through large pharma from feasibility to commercial supply.

What Microsize does

Microsize is a US-headquartered pharmaceutical contract development and manufacturing organization (CDMO) specializing in particle size reduction, powder classification, and analytical services for small-molecule active pharmaceutical ingredients (APIs) and excipients. The company addresses bioavailability and dissolution challenges for poorly soluble compounds through jet milling and micronization — proprietary equipment designed and built in-house — capable of reducing particles to under 10 microns with ~1 micron variance. Microsize operates three FDA-inspected cGMP facilities totaling over 100,000 sq ft in Quakertown, Pennsylvania, and acquired a fourth GMP facility in Monteggio, Switzerland (Micro-Macinazione) from Lonza in May 2026, creating a dual US-European particle engineering platform.

The company offers end-to-end services spanning feasibility studies (as little as 1-5 grams of API), Phase I-III clinical manufacturing, and commercial production campaigns at multi-metric-ton scale. Differentiated capabilities include Co-Jet Milling (combined size reduction and blending), HPAPI containment qualified to OEB 6 (down to 50 ng/m³), air-swept turbo classification for hydrate stability, and advanced analytical characterization (XRPD, DSC, TGA, DVS, laser diffraction). Microsize has expanded beyond toll micronization into a broader particle engineering ecosystem through partnerships with AustinPx (KinetiSol), The Solubility Company (SPA platform licensing — Microsize is the first US licensee), Persist AI (Micromill platform), and Aspire Biopharma (sublingual alprazolam and aspirin development).

Microsize generates revenue through project-based professional services contracts with pharmaceutical companies ranging from small biotechs to large pharma, as well as other CDMOs and functional excipient manufacturers. Pricing is quote-based, dependent on API type, potency, batch size, and development phase. GTM is high-touch, enterprise field sales with direct technical engagement, supplemented by conference presence (CPhI, ChemOutsourcing), technical whitepapers, and LinkedIn-driven brand building. The company is privately held, launched as an independent entity in July 2022 after separation from Lonza, and inherits the 30-year operational heritage of predecessor Powdersize Inc.

Microsize firmographics

Firmographics
Name
Microsize
Legal name
Microsize LLC
Website
https://microsize.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Microsize is a US-headquartered pharmaceutical CDMO specializing in jet milling, micronization, and particle engineering for poorly soluble APIs, operating three FDA-inspected cGMP facilities across 100,000+ sq ft and serving small biotechs through large pharma from feasibility to commercial supply.
Ownership category
akta.pro rank

Microsize industry classification

Industry
Product category
Pharmaceutical CDMO Services
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Plastics Products, Nec (3089)
akta.pro industry
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Pharmaceutical micronization
  • Particle size reduction
  • Contract development manufacturing
  • Bioavailability enhancement
  • HPAPI containment

Where Microsize is headquartered

Location

Headquarters

HQ city
Quakertown
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Microsize business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Manufacturing Services (CDMO): Microsize provides contract development and manufacturing organization services for pharmaceutical micronization and particle size reduction. Revenue is generated through project-based contracts spanning feasibility studies through commercial production campaigns. The company charges for processing services based on project scope, material quantities, and complexity. Services are provided to small biotechs, mid-size pharmaceutical companies, and large pharma organizations.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Microsize product offering

Product offering

Core offering

Microsize is a US-based pharmaceutical contract development and manufacturing organization (CDMO) providing cGMP micronization and particle size reduction services. The company processes APIs and excipients from grams to multi-metric tons, including highly potent compounds, through three FDA-inspected facilities. Core offerings include particle size reduction (micronization/milling), particle classification, analytical characterization, and high-potency containment services for drug developers addressing dissolution and bioavailability challenges.

Differentiator

Problem solved

Functional benefit

Brands

  • Micromill: First-of-its-kind early-stage formulation platform enabling drug development decisions with milligrams of API, developed in partnership with Persist AI and Micromacinazione.

Products and services

  • Micronization & Particle Size Reduction Services
  • Particle Classification Services
  • Analytical Characterization Services
  • High Potency Containment Services
  • Micromill Platform
  • SPA Platform Licensing

Quantifiable outcome

  • Feasibility assessments completed in one day with minimal API (as little as 1-5 grams)
  • +3 more outcomes

Companies that use Microsize

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Microsize technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Microsize partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core.

  • Persist AIcoreStrategic or Co-development Partner · 3 June 2026Strategic collaboration to launch 'Micromill' platform, the world's first integrated system enabling oral formulation decision-making using only milligrams of API. Combines Micmac's SSM20 mini mill with Persist AI's AI-driven experimentation and process analytical technology.
  • Aspire BiopharmacoreStrategic or Co-development Partner · 4 March 2026Partnership to develop first-ever sublingual alprazolam powder formulation for faster anxiety relief. Phase 1 clinical trial planned for mid-2026, targeting a medication with over 15.8 million US prescriptions in 2023.
  • Schedio GroupcoreStrategic or Co-development Partner · 24 November 2025Joint acquisition of Micro-Macinazione (Micmac) from Lonza to establish integrated European-American network for advanced particle engineering. Schedio contributes process equipment and containment technologies while Microsize provides CDMO expertise. Transaction closed May 2026.
  • The Solubility CompanycoreTechnology or Integration · 16 October 2025Microsize became the first US licensee for The Solubility Company's SPA platform, a novel solubility measuring technology. Strategic investment to accelerate US expansion of this disruptive technology.
  • AFT PharmaceuticalscoreStrategic or Co-development Partner · 1 March 2024Expanded CDMO relationship for commercial supply of MAXIGESIC/COMBOGESIC products with investments in capacity expansion.
  • Cerus CorporationcoreStrategic or Co-development Partner · 26 February 2024Expanded CDMO relationship with Cerus Corporation for pharmaceutical manufacturing services.
  • AustinPxcoreTechnology or Integration · 31 January 2024Partnership on KinetiSol technology for novel particle size technology, enabling development of products using this advanced formulation approach.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Microsize competitors and assessment

Company assessment

Direct peers

  • Halo Pharma: Halo Pharma is a specialty CDMO focused on oral solid dosage form development and manufacturing. It competes with Microsize for bioavailability-limited drug product work where particle engineering and formulation overlap, particularly for small and mid-size pharma customers.
  • Hovione: Hovione is a Portugal-headquartered global CDMO with deep particle engineering and jet milling capabilities for small-molecule APIs. It competes most directly with Microsize across micronization, HPAPI containment, and bioavailability-enhancement services, serving similar biotech-to-big-pharma customers with overlapping technology offerings.
  • Ascendia Pharmaceuticals: Ascendia Pharmaceuticals is a specialty CDMO focused on nano-milling and formulation development for poorly soluble compounds. It directly competes with Microsize in providing bioavailability-enhancement and particle engineering services, often at similar early-stage customer touchpoints.
  • Lubrizol Life Sciences (Particle Sciences): Lubrizol Life Sciences, through its Particle Sciences business, is a CDMO focused on particle engineering, formulation development, and drug product manufacturing. It directly competes with Microsize in micronization and bioavailability-enhancement services for poorly soluble APIs across a similar customer base of small to mid-size pharma.

Broad incumbents

  • Lonza: Lonza is one of the largest global CDMOs and historically operated the Quakertown and Micro-Macinazione facilities that Microsize acquired. While Lonza offers micronization as part of a far broader CDMO portfolio, its scale and breadth make it a frequent alternative or competitor for bioavailability-limited small-molecule programs.
  • Evotec: Evotec is a global contract development and manufacturing organization with capabilities spanning drug substance, drug product, and integrated pharmaceutical services. It competes with Microsize for formulation and bioavailability-enhancement projects, particularly with European biotech customers after Microsize's Micro-Macinazione expansion.
  • Catalent: Catalent is a large global CDMO offering a wide range of drug product services including particle engineering, bioavailability enhancement, and HPAPI handling. It competes with Microsize at the high end of the market by bundling micronization into broader end-to-end development and manufacturing contracts.
  • Thermo Fisher Scientific (Patheon): Thermo Fisher's pharma services business, built around Patheon, is a major global CDMO offering drug substance, drug product, and bioavailability-enhancement services. It is a broad incumbent competitor for Microsize's biotech and large pharma customers across micronization-adjacent formulation work.
  • Eurofins CDMO: Eurofins operates a CDMO and contract testing portfolio that overlaps with Microsize's analytical characterization and formulation-support offerings. It is a broader incumbent that competes for outsourced pharmaceutical development and quality services across both US and European markets.

Emerging players

  • Aprecia Pharmaceuticals: Aprecia is a specialty pharma company and CDMO using binder-jetting 3D printing for oral dosage forms. It is an emerging player in the broader particle-engineering and bioavailability space, intersecting with Microsize's territory through novel oral drug delivery approaches for poorly soluble compounds.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

Microsize social profiles

Digital presence

Microsize financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Microsize leadership team

Management profile

Number of profiles

Profiles4 records

Microsize subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Microsize funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Microsize M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Microsize

What does Microsize do?

Microsize is a US-based pharmaceutical contract development and manufacturing organization (CDMO) providing cGMP micronization and particle size reduction services. The company processes APIs and excipients from grams to multi-metric tons, including highly potent compounds, through three FDA-inspected facilities. Core offerings include particle size reduction (micronization/milling), particle classification, analytical characterization, and high-potency containment services for drug developers addressing dissolution and bioavailability challenges.

Is Microsize a public or private company?

Microsize is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Microsize founded?

Microsize was founded in 2022. It employs 11 to 50 people.

Where is Microsize based?

Microsize is headquartered in Quakertown, United States, in the North America region.

How does Microsize make money?

One revenue line is on record: contract Manufacturing Services (CDMO).

Who are Microsize's main competitors?

Direct peers on record are Halo Pharma, Hovione, Ascendia Pharmaceuticals and Lubrizol Life Sciences (Particle Sciences). Broad incumbents are Lonza, Evotec, Catalent, Thermo Fisher Scientific (Patheon) and Eurofins CDMO. Aprecia Pharmaceuticals is listed as an emerging player.

Does Microsize have an API?

No public API is recorded for Microsize.

What industry is Microsize in?

Microsize's product category is Pharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 3254 and its SIC code is 3089.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AijournPersist AI Teams up with Microsize and Micromacinazione (Micmac) to Launch First-of-Its-Kind Early-Stage “Micromill” Formulation Platform, Enabling Drug Development Decision With Milligrams of APIPersist AI has collaborated with Microsize and Micromacinazione to develop the 'Micromill' platform, enabling early-stage drug formulation decisions using milligrams of API. This integrated platform provides a complete workflow from solubility studies to stability assessments, reducing the need for larger quantities of materials and accelerating drug development timelines.PR NewswirePersist AI Teams up with Microsize and Micromacinazione (Micmac) to Launch First-of-Its-Kind Early-Stage "Micromill" Formulation Platform, Enabling Drug Development Decision With Milligrams of APIPersist AI announced a strategic collaboration with Microsize and Micromacinazione (Micmac) to launch the 'Micromill' platform, the world's first integrated system enabling oral formulation decision-making using only milligrams of active pharmaceutical ingredient instead of grams. The platform combines Micmac's SSM20 mini mill with Persist AI's AI-driven experimentation and proprietary process analytical technology to enable go/no-go decisions on micronization and bioavailability strategies at the earliest drug development stages. Microsize recently acquired Micmac along with Schedio Group, creating an integrated global micronization platform with dual-source manufacturing capability across Microsize's FDA-inspected US facilities and Micmac's GMP-inspected operations in Switzerland.Stock TitanAspire Biopharma, Microsize to develop sublingual alprazolamAspire Biopharma Holdings, Inc. announced a strategic partnership with Microsize to develop a novel sublingual powder formulation of alprazolam, the active ingredient in the anti-anxiety medication Xanax, designed to bypass the digestive system for faster and more predictable relief of anxiety disorders and panic attacks. The collaboration aims to create the first-ever sublingual alprazolam powder with a Phase 1 clinical trial planned for mid-2026, supported by Pace as the testing and analytical lab partner. Alprazolam was the 37th most prescribed medication in the United States in 2023 with over 15.8 million prescriptions, and the global alprazolam powder market is projected to reach $55.84 billion by 2032.NewswireAspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety ReliefAspire Biopharma has partnered with Microsize to develop the first-ever sublingual alprazolam powder formulation for faster anxiety relief, targeting what the companies describe as an unmet need for rapid-onset anxiety medication. The two companies plan to initiate a Phase 1 clinical trial for the patent-pending, rapid-onset formulation in mid-2026, addressing a medication that recorded over 15.8 million prescriptions in the US in 2023, making it a top 40 prescribed drug in the country. The collaboration aims to create a differentiated delivery format for alprazolam, potentially offering patients a faster-acting alternative to existing formulations.YahooAspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety ReliefAspire Biopharma partnered with Microsize to develop a rapid-delivery sublingual powder formulation of alprazolam, aiming for a Phase 1 clinical trial planned in mid-2026. This development addresses the need for faster anxiety relief compared to traditional oral tablets. The project involves advanced particle engineering and drug formulation expertise.Business Wire BlogMicrosize and Schedio Group to Acquire Lonza’s Micro-Macinazione Site in SwitzerlandMicrosize and Schedio Group have signed an agreement to jointly acquire Micro-Macinazione (Mic Mac), a GMP-compliant micronization facility in Monteggio, Switzerland, from Lonza. The acquisition represents Microsize's second purchase from Lonza following its 2022 acquisition of the Quakertown, Pennsylvania site, with Schedio investing alongside to strengthen its European operational base. The transaction, expected to close in Q1 2026 subject to customary conditions, aims to establish an integrated European-American network for advanced particle engineering combining Microsize's CDMO expertise with Schedio's process equipment and containment technologies.ContractpharmaMicrosize Signs Long-Term Supply Agreement with Cerus CorporationMicrosize signed a long-term supply agreement with Cerus Corporation to provide high-throughput particle sizing services for powders in the INTERCEPT Blood System for Plasma. The deal includes a joint CAPEX investment to build manufacturing capacity and qualify a higher-throughput processing train in 2023, supporting existing and future demand for plasma and cryoprecipitate.ContractpharmaAustinPx Partners with Microsize on KinetiSol TechnologyAustinPx partnered with Microsize to commercialize its KinetiSol technology, which generates amorphous solid dispersions without solvents. AustinPx will transfer equipment and know-how to Microsize's Quakertown facility, with GMP production projected by end of 2024.Business Wire BlogAustinPx Partners with Microsize on KinetiSol® TechnologyAustinPx and Microsize announced a partnership to commercialize AustinPx's KinetiSol technology, which uses frictional and shear energies to create amorphous solid dispersions. AustinPx will transfer its equipment and know-how to Microsize's Quakertown facility, with GMP production projected by end of 2024.